Laboratory of Protein Biochemistry and Pathology

Andrey V. Lisitsa Head of Lab D.Sc., Acad.

CONTACTS +7 (499) 246-50-72

Olga S. Timoshenko Ph.D.	Irina I. Karuzina D.Sc.	Elena V. Kugaevskaya Ph.D.
Natalia A. Petushkova Ph.D.	Sergej P. Radko Ph.D.	Tatiana A. Gureeva Ph.D.
Leonid K. Kurbatov Ph.D.	Juliana S. Kisrieva Ph.D.	Konstantin G. Ptitsyn Ph.D.
Natalia F. Samenkova Ph.D.	Svetlana A. Khmeleva Ph.D.	Nikita A. Bolochenkov
Yuliana A. Vasilieva	Yaroslav V. Demenchuk	Aleksei V. Zgoda
Ivan A. Kolosov	Danila D. Kotelnikov	Vasily A. Kuryshev
Ekaterina V. Lyamtseva	Daria D. Morozova	Elizaveta A. Nikishina

CURRENT DIRECTIONS

Fundamental studies of the mechanisms of drug biotransformation and a feasibility of its modulation on the cell lines of hepatocyte origin, using omics technologies, bioinformatics, and cell technologies

Development of diagnostic systems to ensure biosafety in agriculture and the food industry

Analysis of influence of key genes of the embryonic differentiation signaling pathway (Hh) on the expression of matrix metalloproteinases (MMPs) in cervical carcinoma

Sequencing the human cell transcriptomes with the "long reads" (nanopore sequencing) and the adaptation of cloud technologies for the analysis of long-read sequencing data

The Laboratory of Biochemistry and Chemical Pathology of Proteins was established in 1944 by Academician, Prof. V.N. Orekhovich, simultaneously with the foundation of IBMС. Prof. Orekhovich headed the Laboratory for more than 40 years. From 1988 to 2022, the head of the Laboratory was Prof. N.I. Solovyеvа who was an apprentice and coworker of V.N. Orekhovich for long years. The main research area of the Laboratory was the study of the structure and function of proteolytic enzymes and their role in the pathogenesis of various human diseases.

In 2023, the Laboratory was merged under the leadership of Academician, Prof. A.V. Lisitsa with two other structural divisions of IBMC, the Laboratory of Microsomal Oxidation and the Unit on Tanscriptome Analysis, retaining its name. The current focus of the Laboratory is on integrating omics technologies, bioinformatics, and cell technologies (in cooperation with other divisions of IBMC) to develop human liver cell models for the investigation of drug biotransformation and the toxicity evaluation. Also, the Laboratory aims to develop approaches to DNA diagnostics of infectious diseases in a format of “point-of-need testing”, based on isothermal amplification of nucleic acids and its combination with the selective CRISPR/Cas-detection of target amplicons.

PROJECTS

• The fundamental research aimed at creating new diagnostic systems and ensuring biosafety conditions in the food sector.
• The applied research aimed at detecting ultra-low concentrations of nucleotide sequences of bacteria and viruses in the frame of Genetic Technology Development Program of the Russian Federation./li>

ACHIEVEMENTS

• The physicochemical properties, chemical composition, structure and metabolism of connective tissue proteins, in particular collagens, were established in physiological and pathological conditions. These studies were awarded the medal of the II International Biochemical Congress in 1952 and the medal of the Biochemical Union of France in 1955. The work on the study of eye proteins – crystallins – was awarded the Pasteur Medal in 1957.
• Three tissue proteases have for the first time been discovered, characterized and included in the International Nomenclature of Enzymes: angiotensin converting enzyme (ACE) – CF 3.4.15.1 (1970); ribosomal protease, cathepsin R – CF 3.4.99.33 (1975, 1978); prolylendopeptidase (PEP) – CF 3.4.22.18 (1976; 1979).
• There has been proven that cytochromes P450 can be drivers of the development of socially significant diseases (1981-1997).
• A new property of ACE was discovered – the ability to hydrolyze the Arg5-His6 bond in the beta-amyloid peptide, the main component of senile plaques accumulating in the brain of patients with Alzheimer's disease (2008).
• The role of matrix metalloproteinases (MMPs) as key factors of invasion and metastasis in squamous cell cervcal carcinoma was established (1998-2022).
• Transcriptomic-proteomic profiling of human cell lines and tissues in norm and pathology was carried out (2012-2024).